Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial
- Sponsor
- Tor Biering-Sørensen
- Study ID
- NCT07382414
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Coronary Artery Disease
- Hypercholesterolemia
- Lipoprotein(a)
- Secondary Prevention
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- LDL-C information letter — BEHAVIORALAn electronically delivered informational letter communicating the participant's elevated LDL-C level and its relevance to ASCVD, with encouragement to consult their physician if relevant. Delivered via the Danish Digital Post system.
- Lp(a) information letter — BEHAVIORALAn electronically delivered informational letter describing elevated Lp(a) as a genetically determined cardiovascular risk factor, with encouragement to discuss risk factor optimization with a physician if relevant.
Study Details
The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) \[Lp(a)\] will also be randomized to receive an additional information letter. The main questions the study aims to answer are: * Does sending an electronic letter about elevated LDL cholesterol increase the proportion of patients who have at least one LDL-cholesterol test within 6 months? * Among patients with ischemic heart disease and elevated Lp(a), does receiving an information letter about Lp(a) increase patient activation, reflected by cardiometabolic risk-factor monitoring? Because this is a randomized trial, researchers will compare people who receive the electronic letter(s) with people who do not receive any letter to determine whether the letters encourage patients to take action, such as obtaining laboratory tests or contacting their doctor. Participants will: * Receive an electronic letter through Denmark's national digital mailbox system (Digital Post) or receive no letter, depending on random assignment. * Continue their usual health care, with no additional visits, treatments, or procedures required for the study. * Have all study information collected from existing Danish nationwide health registries.
Key Dates
- First listed
- Feb 2, 2026
- Start date
- Apr 30, 2026
- Status verified
- Jan 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 100,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: LDL letter onlyParticipants randomized to the LDL-C letter but not the Lp(a) letter
- Experimental: Lp(a) letter onlyParticipants randomized to the Lp(a) letter but not the LDL-C letter.
- No Intervention: No letterParticipants randomized to no LDL-C letter and to no Lp(a) letter
- Experimental: LDL-C and Lp(a) letterParticipants randomized to the LDL-C letter and the Lp(a) letter
Primary Outcome Measure
the proportion of participants with at least one LDL-C measurement within 6 months following randomization [ Time Frame: 6 months after randomization ]
Central Contacts
- Tor Biering-Sørensen, MD, MPH, MSc, PhD28933590
Related Studies
- Causes and Natural History of DyslipidemiasRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)PHASE2 · Not Yet Recruiting · Cell>Point LLC · Oklahoma City, Oklahoma